Ibrance and Sinusitis bacterial - a phase IV clinical study of FDA data

Summary:

Sinusitis bacterial is reported as a side effect among people who take Ibrance (palbociclib), especially for people who are female, 60+ old, also take Letrozole, and have Breast cancer female.

The phase IV clinical study analyzes which people have Sinusitis bacterial when taking Ibrance. It is created by eHealthMe based on reports of 104,340 people who have side effects when taking Ibrance from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.

What is Sinusitis bacterial?

Sinusitis bacterial (bacterial infection of sinus) is found to be associated with 202 drugs and 159 conditions by eHealthMe. Check the latest studies of Sinusitis bacterial.



On Dec, 19, 2025

104,340 people reported to have side effects when taking Ibrance.
Among them, 9 people (0.01%) have Sinusitis bacterial.

Could Ibrance cause Sinusitis bacterial?

Among these 9 people:

What is the gender of people who have Sinusitis bacterial when taking Ibrance? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Sinusitis bacterial when taking Ibrance? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 11.11 %
  • 50-59: 22.22 %
  • 60+: 66.67 %

What are other drugs people take besides Ibrance? *

  1. Letrozole: 4 people, 44.44%
  2. Vitamin B12: 2 people, 22.22%
  3. Simvastatin: 2 people, 22.22%
  4. Clonidine: 2 people, 22.22%
  5. Biotin: 2 people, 22.22%
  6. Atenolol: 2 people, 22.22%
  7. Amlodipine: 2 people, 22.22%
  8. Zolpidem: 1 person, 11.11%
  9. Ondansetron: 1 person, 11.11%
  10. Flexeril: 1 person, 11.11%

What are other side effects people have besides Sinusitis bacterial? *

  1. White Blood Cell Count Decreased: 2 people, 22.22%
  2. Arthropathy: 2 people, 22.22%
  3. Therapeutic Response Unexpected: 2 people, 22.22%
  4. Eating Disorder: 2 people, 22.22%
  5. Fatigue (feeling of tiredness): 2 people, 22.22%
  6. Hair Loss: 2 people, 22.22%
  7. Mucormycosis (a rare infection caused by organisms that belong to a group of fungi called mucoromycotina): 2 people, 22.22%
  8. Nasal Dryness (dry nose): 1 person, 11.11%
  9. Bone Pain: 1 person, 11.11%
  10. Diarrhea: 1 person, 11.11%

What are the existing conditions these people have? *

  1. Breast Cancer Female: 5 people, 55.56%
  2. Breast Cancer Metastatic: 2 people, 22.22%
  3. Breast Cancer: 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and have Sinusitis bacterial?

- Check whether Sinusitis bacterial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Sinusitis bacterial treatments and more:

How severe was Sinusitis bacterial and when was it recovered:

Expand to all the drugs that have ingredients of palbociclib:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sinusitis bacterial:

Browse all the conditions that are associated with Sinusitis bacterial:


How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: